SILENCE THERAPEUTICS PLC-ADR (SLN)

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024

Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

7 Biotech Stocks Ready to Ride the Sector’s Resurgence

With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.

These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results

Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday.

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Silence Therapeutics receives $10M payment from AstraZeneca collaboration (NASDAQ:SLN)

Silence Therapeutics receives $10M milestone payment from AstraZeneca as the first product candidate in their siRNA collaboration enters phase 1 clinical...

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Silence Therapeutics announces oversubscribed $120M private placement (NASDAQ:SLN)

Silence Therapeutics raises $120M through oversubscribed private placement for clinical development and corporate purposes. Offering to close on Feb.

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Silence Therapeutics GAAP EPS of -7.40, revenue of £2.8M (NASDAQ:SLN)

Silence Therapeutics reports Q3 GAAP EPS of -$7.40 and revenue of $2.8M (-17.6% Y/Y) in its recent press release.

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Silence Therapeutics is Now Oversold (SLN)

Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference

Silence Therapeutics (SLN) Shares Cross Above 200 DMA

Silence Therapeutics to Participate in September Investor Conferences

Silence Therapeutics Reports Second Quarter 2023 Results

Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

Silence Therapeutics to Present at the Jefferies Healthcare Conference

Silence Therapeutics Reports First Quarter 2023 Results